Rx Networks Introduces TruePoint | FOCUS: Unlocking Instantaneous Centimeter-Level Accuracy for the Masses
8.4.2025 16:00:00 CEST | Business Wire | Press Release
Leading GNSS data services provider, Rx Networks, unveils TruePoint | FOCUS, a high-precision cloud-based GNSS correction service delivering instantaneous centimeter-level accuracy across a wide range of applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250408494006/en/
Rx Networks launches TruePoint | FOCUS: Instantaneous Centimeter-Level Accuracy, Effortless setup, Unmatched reliability, Designed for any scale.
TruePoint | FOCUS is designed to meet the demands of applications that require real-time precision without compromise. It supports both RTK (OSR) and PPP-RTK (SSR) modes to deliver flexibility and performance across a range of devices and use cases. The service empowers GNSS receivers with centimeter-level positioning accuracy, enabling a wide array of high-precision use cases in industries such as micro-mobility, smart agriculture, robotics, drones, IoT, and machine control.
The RTK mode is fully hardware-agnostic and compatible with all RTK-capable GNSS receivers, removing the limitations imposed by proprietary ecosystems. TruePoint | FOCUS ensures effortless integration through standard correction protocols like RTCM v3, and supports access via NTRIP, allowing for rapid deployment and minimal integration effort.
In PPP-RTK mode, users can benefit from advanced SSR-based delivery, achieving high-accuracy positioning with optimized bandwidth. TruePoint | FOCUS also supports more GNSS signals than most competing solutions, delivering enhanced resilience and performance in challenging environments.
“Precision means nothing without reliability,” said John Carley, CEO at Rx Networks. “TruePoint | FOCUS is built on the same ultra-reliable server architecture that powers our Location.io service, which supports critical applications worldwide, ensuring our customers get the accuracy they need, every time.”
TruePoint | FOCUS delivers consistent centimeter-level accuracy with a 99.9% SLA. Its seamless coverage and real-time performance make it ideal for companies operating across North America, Europe, China, and beyond. The correction stream is configurable and includes all available signals across GPS, Galileo, and BeiDou constellations, making TruePoint | FOCUS one of the most comprehensive GNSS correction services on the market.
“With this launch, Rx Networks expands the TruePoint portfolio to include LITE, REACH, and now FOCUS,” said Ali Soliman, VP of Sales and Marketing at Rx Networks. “Together, these offerings address a wide range of use cases balancing accuracy, coverage, cost and hardware compatibility to support the next generation of GNSS applications.”
TruePoint | FOCUS is available today for trial in both RTK and PPP-RTK modes across the covered regions, with more new areas on the roadmap. Users can sign up for a complimentary 30-day trial license at http://www.rxnetworks.com/request-a-free-trial. For further inquiries, contact sales@rxnetworks.com.
About Rx Networks Inc.
Rx Networks is a Canadian company that provides reliable, timely, and relevant location assistance and correction data that improves the GNSS experience and strengthen the connection between people. Billions of devices benefit from Rx Networks GNSS data services every day.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250408494006/en/
Contacts
Rx Networks Inc.
Ali Soliman
VP of Sales and Marketing
asoliman@rxnetworks.com
+1 408 734 6551
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom